Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Procuritas in connection with the sale of Ouriginal Group
Mandate

Vinge has advised Procuritas in connection with the sale of Ouriginal Group

January 07, 2022 EU, Competition and Regulatory IT, Telecommunications and Outsourcing M&A Intellectual Property

Vinge has advised Procuritas, the private equity investor focused on investing in and growing Nordic mid-market companies, in connection with the sale of Ouriginal Group to Turnitin LLC, a global leader in academic integrity and education software.

Ouriginal, a company formed from the union of Urkund and PlagScan, has over three decades of experience in combining text-matching with writing-style analysis to promote academic integrity and prevent plagiarism in schools and universities.

Vinge’s team consisted of Jonas Johansson, Karl Klackenberg and Ellinor Wargenbrant (M&A), Mathilda Persson (IT), Tobias Kempas (IP), Sebastian Örndahl and Victoria Fredén (Competition) and Viktoria Owetz Leyva (VDR).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026